To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
Summary
HR8857 is an early-stage bill that would exempt engineered cyclic peptides from Medicare drug price negotiation. It has minimal near-term market impact due to its procedural status and lack of specific drug identification. No funding is authorized.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8857 is in the earliest legislative stage with low momentum.
- 2.No funding is authorized; the bill is a regulatory exemption.
- 3.JNJ and LLY are potential beneficiaries but the impact is speculative.
Market Implications
The bill has negligible near-term market implications. If it advances, it could modestly benefit pharmaceutical companies with cyclic peptide drugs by shielding them from Medicare negotiation. However, the lack of specificity and early legislative stage mean no actionable signal for retail investors now.
Full Analysis
-
On May 15, 2026, Rep. Morelle (D-NY) introduced HR8857, which amends the Social Security Act to adjust which engineered cyclic peptides qualify as single source drugs under the Drug Price Negotiation Program. The bill was referred to both the Energy and Commerce and Ways and Means Committees. It is in the earliest legislative stage with only 4 actions (introduction and referral).
-
The bill does not authorize or appropriate any funding. It is a regulatory change that would exempt certain drugs from Medicare price negotiation, thereby preserving their market pricing. The exact drugs affected are not specified, making revenue impact estimates impossible.
-
Potential beneficiaries are pharmaceutical companies with engineered cyclic peptide drugs in their portfolios. JNJ and LLY are the largest publicly traded companies with significant cyclic peptide-based therapies. However, the bill is too vague to determine which specific products are affected, and the legislative path is long.
-
No real market data is provided for stock prices. The competitive landscape for cyclic peptide drugs includes both large pharma and smaller biotechs, but the bill's early stage limits actionable conclusions.
-
The bill must pass both committees, the House, the Senate, and be signed by the President. With only 3 cosponsors and a junior sponsor, passage probability is low in the current Congress. No companion bill exists in the Senate.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Same as above — amends the definition of 'qualifying single source drug' to exclude engineered cyclic peptides from Medicare price negotiation.
Who must act
Centers for Medicare & Medicaid Services (CMS) — must adjust the list of drugs eligible for negotiation.
What happens
If enacted, specific engineered cyclic peptide drugs would be exempt from Medicare price negotiation, preserving their market pricing.
Stock impact
LLY's portfolio includes cyclic peptide-based drugs (e.g., certain diabetes and oncology therapies). Exemption from negotiation protects revenue from these products, though the exact drugs are not specified.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Women's Health to Improve Outcomes in All Phases of Life
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →